株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ファーマコビジランスの世界市場:治験段階、サービス業者、種類、最終用途、セグメント別の分析と予測

Pharmacovigilance (PV) Market Analysis By Clinical Trial Phase (Pre-Clinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-House, Contract Outsourcing), By Type, By End UseAnd Segment Forecasts, 2014 - 2025

発行 Grand View Research, Inc. 商品コード 544763
出版日 ページ情報 英文 129 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
ファーマコビジランスの世界市場:治験段階、サービス業者、種類、最終用途、セグメント別の分析と予測 Pharmacovigilance (PV) Market Analysis By Clinical Trial Phase (Pre-Clinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-House, Contract Outsourcing), By Type, By End UseAnd Segment Forecasts, 2014 - 2025
出版日: 2017年07月10日 ページ情報: 英文 129 Pages
概要

当レポートでは、世界のファーマコビジランス (PV:医薬品安全性監視) 市場について分析し、技術の特性や市場の基本的構造、主な市場促進・抑制要因、全体的な市場規模の動向見通し (過去3年間・今後9年間分)、治験段階・サービス業者・治療手段・最終用途別、および地域別の詳細動向、市場競争環境 (市場シェア・求心力ほか)、主要企業のプロファイル・業績などを調査しております。

第1章 分析手法

第2章 エグゼクティブ・サマリー

第3章 ファーマコビジランス市場:市場データ・傾向・展望

  • 市場の内訳と範囲
  • 市場促進要因の分析
  • 市場抑制要因の分析
  • 市場浸透度・成長率の見通し
  • SWOT分析
  • 産業分野:ポーターのファイブフォース・モデル

第4章 ファーマコビジランス市場:治験段階別の予測値と動向分析

  • 治験段階別の動向分析
  • 前臨床
  • 第I相
  • 第II相
  • 第III相
  • 第VI相

第5章 ファーマコビジランス市場:サービス業者別の予測値と動向分析

  • サービス業者 (サービスプロバイダー) 別の動向分析
  • 内製型企業
  • 外注型企業

第6章 ファーマコビジランス市場:治療手段別の予測値と動向分析

  • 手段別の動向分析
  • 自発報告
  • 強化型ADR (医薬品有害反応) 報告
  • 標的特定型自発報告
  • コホート・イベントモニタリング
  • 電子カルテ (EHR) マイニング

第7章 ファーマコビジランス市場:最終用途別の予測値と動向分析

  • 最終用途 (エンドユース) 別の市場動向の分析
  • 病院
  • 研究機関
  • 各種産業

第8章 ファーマコビジランス市場:地域別の予測値と動向分析

  • 地域別の市場シェア (最新値、予測値)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競争環境

  • 企業戦略のフレームワーク
  • 市場参入企業
  • 企業プロファイル
目次
Product Code: 978-1-68038-327-0

The global pharmacovigilance (PV) market is expected to reach USD 10.27 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness growth at 13.1% CAGR owing to Increasing incidence of ADR is key driver for the growth of pharmacovigilance market. As of 2015, the U.S. FDA received approximately 253,017 serious adverse events and 44,693 deaths associated with adverse drug reactions (ADRs). This shows the potential demand for implementing safety and pharmacovigilance services over the forecast period

According to World Health Organization's (WHO) report on pharmaceuticals consumption, medicines to treat chronic diseases accounted for a larger proportion of the total volume of drug consumption in non-hospital set ups. Owing to this, there has been a significant rise in the number of medicines made available to healthcare consumers. Rising demand for drugs has significantly heightened the need for novel therapeutics development via extensive clinical trials, which is further expected to serve this market with lucrative opportunities.

Major pharmaceutical companies are involved in extensive R&D initiatives for development of innovative therapeutic molecules. This has resulted in increased rate of drug development. Manufacturers are now focusing on remodeling their product development processes in an attempt to cater to patient needs across the globe. These factors are anticipated to fuel the demand for PV services during the forecast period.

Moreover, leading pharma companies in developed countries are focusing toward the outsourcing PV service in an attempt to reduce cost and minimize operational expenses. This is anticipated to serve as opportunity for contact research organizations in developing regions to gain more revenue share.

The companies are undertaking strategic initiatives such as collaboration with the PV service providers to get access to medical information and manage PV workflows. For instance, In April 2017, Accenture entered in a collaborative agreement with BioCelebrate to develop a platform for aggregating and analyzing clinical information for improvement in drug developing efficiency, thus enhancing its R&D capabilities. These factors are anticipated to fuel the market growth.

Further Key Findings From the Study Suggest:

Phase IV held a dominant share owing to the extensive post marketing surveillance of pharmaceuticals and increasing number of ADR incidences in the market

Phase III is anticipated to grow with lucrative CAGR owing to increasing focus of pharmaceutical manufacturers on therapeutic development and safety monitoring

Contract outsourcing held a significant share of the PV market based on service provider owing to the increasing shift of pharmaceutical companies towards outsourcing of PV services with a view to reduce operational cost

Based on the type of service, spontaneous reporting held the largest share owing to its wide application in pharmacovigilance and associated benefits such as easy simulation of data sets for better drug comparison

Research organizations segment is anticipated to exhibit lucrative growth over forecast period owing to increasing R&D for the development of novel biologics and medical devices

The Asia Pacific market for pharmacovigilance is anticipated to show lucrative CAGR in the coming years

The industry participants are focusing towards increasing R&D activities for the development of better pharmacovigilance services.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Country wise market: Base estimates
    • 1.1.1 Global market: CAGR calculation
    • 1.1.2 Region based segment share calculation
  • 1.2 Research Scope & Assumptions
  • 1.3 List of Data Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Growing drug consumption and drug development rates
    • 3.2.2 Increasing incidence rates of ADR and drug toxicity
    • 3.2.3 Increasing trend of outsourcing pharmacovigilance services
  • 3.3 Market Restraint Analysis
    • 3.3.1 Lack of skilled labor
  • 3.4 Penetration & Growth Prospect Mapping
  • 3.5 Pharmacovigilance - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.6 Industry Analysis - Porter's

Chapter 4 Pharmacovigilance Market: Clinical Trial Phase Estimates & Trend Analysis

  • 4.1 Pharmacovigilance Market: Clinical Trial Phase Movement Analysis
  • 4.2 Pre-clinical
    • 4.2.1 Pre-clinical market, 2014 - 2025 (USD Million)
  • 4.3 Phase 1
    • 4.3.1 Phase 1 clinical trial market, 2014 - 2025 (USD Million)
  • 4.4 Phase 2
    • 4.4.1 Phase 2 clinical trial market, 2014 - 2025 (USD Million)
  • 4.5 Phase 3
    • 4.5.1 Phase 3 clinical trial market, 2014 - 2025 (USD Million)
  • 4.6 Phase 4
    • 4.6.1 Phase 4 clinical trial market, 2014 - 2025 (USD Million)

Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

  • 5.1 Pharmacovigilance Market: Service Provider Movement Analysis
  • 5.2 In-house
    • 5.2.1 In-house market, 2014 - 2025 (USD Million)
  • 5.3 Contract Outsourcing
    • 5.3.1 Contract outsourcing market, 2014 - 2025 (USD Million)

Chapter 6 Pharmacovigilance Market: Type of Method Estimates & Trend Analysis

  • 6.1 Pharmacovigilance Market: Type Movement Analysis
  • 6.2 Spontaneous Reporting
    • 6.2.1 Spontaneous reporting market, 2014 - 2025 (USD Million)
  • 6.3 Intensified ADR Reporting
    • 6.3.1 Intensified ADR reporting market, 2014 - 2025 (USD Million)
  • 6.4 Targeted Spontaneous Reporting
    • 6.4.1 Targeted spontaneous reporting market, 2014 - 2025 (USD Million)
  • 6.5 Cohort Event Monitoring
    • 6.5.1 Cohort event monitoring market, 2014 - 2025 (USD Million)
  • 6.6 EHR Mining
    • 6.6.1 EHR mining market, 2014 - 2025 (USD Million)

Chapter 7 Pharmacovigilance Market: End Use Estimates & Trend Analysis

  • 7.1 Pharmacovigilance Market: End Use Movement Analysis
  • 7.2 Hospitals
    • 7.2.1 Hospitals market, 2014 - 2025 (USD Million)
  • 7.3 Research Organizations
    • 7.3.1 Research organizations market, 2014 - 2025 (USD Million)
  • 7.4 Industrial
    • 7.4.1 Industrial market, 2014 - 2025 (USD Million)

Chapter 8 Pharmacovigilance Market: Regional Estimates & Trend Analysis, by Clinical Trial Phase, Service Provider, Type, and End Use

  • 8.1 Pharmacovigilance Market Share by Region, 2016& 2025
  • 8.2 North America
    • 8.2.1 North America pharmacovigilance market, by country, 2014 - 2025 (USD Million)
    • 8.2.2 North America pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
    • 8.2.3 North America pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
    • 8.2.4 North America pharmacovigilance market, by type, 2014 - 2025 (USD Million)
    • 8.2.5 North America pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.2.6 U.S.
      • 8.2.6.1 U.S. pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.2.6.2 U.S. pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.2.6.3 U.S. pharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.2.6.4 U.S. pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.2.7 Canada
      • 8.2.7.1 Canada pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.2.7.2 Canada pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.2.7.3 Canada pharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.2.7.4 Canada pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe pharmacovigilance market, by country, 2014 - 2025 (USD Million)
    • 8.3.2 Europe pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
    • 8.3.3 Europe pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
    • 8.3.4 Europe pharmacovigilance market, by type, 2014 - 2025 (USD Million)
    • 8.3.5 Europe pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.3.6 UK
      • 8.3.6.1 UK pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.3.6.2 UK pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.3.6.3 UK pharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.3.6.4 UK pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.3.7 Germany
      • 8.3.7.1 Germany pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.3.7.2 Germany pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.3.7.3 Germanypharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.3.7.4 Germany pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific pharmacovigilance market, by country, 2014 - 2025 (USD Million)
    • 8.4.2 Asia Pacific pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
    • 8.4.3 Asia Pacific pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
    • 8.4.4 Asia Pacific pharmacovigilance market, by type, 2014 - 2025 (USD Million)
    • 8.4.5 Asia Pacific pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.4.6 Japan
      • 8.4.6.1 Japan pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.4.6.2 Japan pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.4.6.3 Japan pharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.4.6.4 Japan pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.4.7 China
      • 8.4.7.1 China pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.4.7.2 China pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.4.7.3 China pharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.4.7.4 China pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.4.8 India
      • 8.4.8.1 India pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.4.8.2 India pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.4.8.3 India pharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.4.8.4 India pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America pharmacovigilance market, by country, 2014 - 2025 (USD Million)
    • 8.5.2 Latin America pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
    • 8.5.3 Latin America pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
    • 8.5.4 Latin America pharmacovigilance market, by type, 2014 - 2025 (USD Million)
    • 8.5.5 Latin America pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.5.6 Brazil
      • 8.5.6.1 Brazil pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.5.6.2 Brazil pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.5.6.3 Brazil pharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.5.6.4 Brazil pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.5.7 Mexico
      • 8.5.7.1 Mexico pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.5.7.2 Mexico pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.5.7.3 Mexico pharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.5.7.4 Mexico pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • 8.6 MEA
    • 8.6.1 MEA pharmacovigilance market, by country, 2014 - 2025 (USD Million)
    • 8.6.2 MEA pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
    • 8.6.3 MEA pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
    • 8.6.4 MEA pharmacovigilance market, by type, 2014 - 2025 (USD Million)
    • 8.6.5 MEA pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
    • 8.6.6 South Africa
      • 8.6.6.1 South Africa pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
      • 8.6.6.2 South Africa pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
      • 8.6.6.3 South Africa pharmacovigilance market, by type, 2014 - 2025 (USD Million)
      • 8.6.6.4 South Africa pharmacovigilance market, by end use, 2014 - 2025 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Strategy Framework
  • 9.2 Market Participation
  • 9.3 Company Profiles
    • 9.3.1 Accenture
      • 9.3.1.1 Company overview
      • 9.3.1.2 Financial performance
      • 9.3.1.3 Product benchmarking
      • 9.3.1.4 Strategic initiatives
    • 9.3.2 Clinquest Group B.V.
      • 9.3.2.1 Company overview
      • 9.3.2.2 Product benchmarking
      • 9.3.2.3 Strategic initiatives
    • 9.3.3 Cognizant
      • 9.3.3.1 Company overview
      • 9.3.3.2 Financial performance
      • 9.3.3.3 Product benchmarking
      • 9.3.3.4 Strategic initiatives
    • 9.3.4 Laboratory Corporation of America Holdings
      • 9.3.4.1 Company overview
      • 9.3.4.2 Financial performance
      • 9.3.4.3 Product benchmarking
      • 9.3.4.4 Strategic initiatives
    • 9.3.5 IBM Corporation
      • 9.3.5.1 Company overview
      • 9.3.5.2 Financial performance
      • 9.3.5.3 Product benchmarking
      • 9.3.5.4 Strategic initiatives
    • 9.3.6 ArisGlobal
      • 9.3.6.1 Company overview
      • 9.3.6.2 Financial performance
      • 9.3.6.3 Product benchmarking
      • 9.3.6.4 Strategic initiatives
    • 9.3.7 ICON plc
      • 9.3.7.1 Company overview
      • 9.3.7.2 Financial performance
      • 9.3.7.3 Product benchmarking
      • 9.3.7.4 Strategic initiatives
    • 9.3.8 Capgemini
      • 9.3.8.1 Company overview
      • 9.3.8.2 Financial performance
      • 9.3.8.3 Product benchmarking
      • 9.3.8.4 Strategic initiatives
    • 9.3.9 ITClinical
      • 9.3.9.1 Company overview
      • 9.3.9.2 Financial performance
      • 9.3.9.3 Product benchmarking
      • 9.3.9.4 Strategic initiatives
    • 9.3.10 iMEDGlobal
      • 9.3.10.1 Company overview
      • 9.3.10.2 Financial performance
      • 9.3.10.3 Product benchmarking
      • 9.3.10.4 Strategic initiatives
    • 9.3.11 Foresight Group International AG
      • 9.3.11.1 Company overview
      • 9.3.11.2 Financial performance
      • 9.3.11.3 Product benchmarking
      • 9.3.11.4 Strategic initiatives
    • 9.3.12 TAKE Solutions Ltd.
      • 9.3.12.1 Company overview
      • 9.3.12.2 Financial performance
      • 9.3.12.3 Product benchmarking
      • 9.3.12.4 Strategic initiatives
    • 9.3.13 PAREXEL International Corporation
      • 9.3.13.1 Company overview
      • 9.3.13.2 Financial performance
      • 9.3.13.3 Product benchmarking
      • 9.3.13.4 Strategic initiatives
    • 9.3.14 BioClinica
      • 9.3.14.1 Company overview
      • 9.3.14.2 Financial performance
      • 9.3.14.3 Product benchmarking
      • 9.3.14.4 Strategic initiatives
    • 9.3.15 Wipro Ltd.
      • 9.3.15.1 Company overview
      • 9.3.15.2 Financial performance
      • 9.3.15.3 Product benchmarking
      • 9.3.15.4 Strategic initiatives
    • 9.3.16 United BioSource Corporation
      • 9.3.16.1 Company overview
      • 9.3.16.2 Financial performance
      • 9.3.16.3 Product benchmarking
      • 9.3.16.4 Strategic initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America pharmacovigilance market, by country, 2014 - 2025 (USD Million)
  • TABLE 3 North America pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 4 North America pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 5 North America pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 6 North America pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 7 U.S. pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 8 U.S. pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 9 U.S. pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 10 U.S. pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 11 Canada pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 12 Canada pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 13 Canada pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 14 Canada pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 15 Europe pharmacovigilance market, by country, 2014 - 2025 (USD Million)
  • TABLE 16 Europe pharmacovigilance market, by clinical trial phase, 2014 - 2025(USD Million)
  • TABLE 17 Europe pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 18 Europe pharmacovigilance market, by type, 2014 - 2025(USD Million)
  • TABLE 19 Europe pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 20 UK pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 21 UK pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 22 UK pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 23 UK pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 24 Germany pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 25 Germany pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 26 Germany pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 27 Germany pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 28 Asia Pacific pharmacovigilance market, by country, 2014 - 2025 (USD Million)
  • TABLE 29 Asia Pacific pharmacovigilance market, by clinical trial phase, 2014 - 2025(USD Million)
  • TABLE 30 Asia Pacific pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 31 Asia Pacific pharmacovigilance market, by type, 2014 - 2025(USD Million)
  • TABLE 32 Asia Pacific pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 33 Japan pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 34 Japan pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 35 Japan pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 36 Japan pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 37 China pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 38 China pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 39 China pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 40 China pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 41 India pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 42 India pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 43 India pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 44 India pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 45 Latin America pharmacovigilance market, by country, 2014 - 2025 (USD Million)
  • TABLE 46 Latin America pharmacovigilance market, by clinical trial phase, 2014 - 2025(USD Million)
  • TABLE 47 Latin America pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 48 Latin America pharmacovigilance market, by type, 2014 - 2025(USD Million)
  • TABLE 49 Latin America pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 50 Brazil pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 51 Brazil pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 52 Brazil pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 53 Brazil pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 54 Mexico pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 55 Mexico pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 56 Mexico pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 57 Mexico pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 58 MEA pharmacovigilance market, by country, 2014 - 2025 (USD Million)
  • TABLE 59 MEA pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 60 MEA pharmacovigilance market, by service provider, 2014 - 2025 (USD Million)
  • TABLE 61 MEA pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 62 MEA pharmacovigilance market, by end use, 2014 - 2025 (USD Million)
  • TABLE 63 South Africa pharmacovigilance market, by clinical trial phase, 2014 - 2025 (USD Million)
  • TABLE 64 South Africa pharmacovigilance market, by service provider, 2014 - 2025(USD Million)
  • TABLE 65 South Africa pharmacovigilance market, by type, 2014 - 2025 (USD Million)
  • TABLE 66 South Africa pharmacovigilance market, by end use, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends &outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Penetration & growth prospect mapping
  • FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 8 Porter's Five Forces Analysis
  • FIG. 9 Pharmacovigilance market, clinical trial phase outlook: Key takeaways
  • FIG. 10 Pharmacovigilance market: Clinical trial phase movement analysis
  • FIG. 11 Pre-clinical market, 2014 - 2025 (USD Million)
  • FIG. 12 Phase 1 clinical trial market, 2014 - 2025 (USD Million)
  • FIG. 13 Phase 2 clinical trial market, 2014 - 2025 (USD Million)
  • FIG. 14 Phase 3 clinical trial market, 2014 - 2025 (USD Million)
  • FIG. 15 Phase 4 clinical trial market, 2014 - 2025 (USD Million)
  • FIG. 16 Pharmacovigilance market, service provider outlook: Key takeaways
  • FIG. 17 Pharmacovigilance market: Service provider movement analysis
  • FIG. 18 In-house market, 2014 - 2025 (USD Million)
  • FIG. 19 Contract outsourcing market, 2014 - 2025 (USD Million)
  • FIG. 20 Pharmacovigilance market, type outlook: Key takeaways
  • FIG. 21 Pharmacovigilance market: Type movement analysis
  • FIG. 22 Spontaneous reporting market, 2014 - 2025 (USD Million)
  • FIG. 23 Intensified ADR reporting market, 2014 - 2025 (USD Million)
  • FIG. 24 Targeted spontaneous reporting market, 2014 - 2025 (USD Million)
  • FIG. 25 Cohort event monitoring market, 2014 - 2025 (USD Million)
  • FIG. 26 EHR mining market, 2014 - 2025 (USD Million)
  • FIG. 27 Pharmacovigilance market, end use outlook: Key takeaways
  • FIG. 28 Pharmacovigilance market: End use movement analysis
  • FIG. 29 Hospitals market, 2014 - 2025 (USD Million)
  • FIG. 30 Research organizations market, 2014 - 2025 (USD Million)
  • FIG. 31 Industrial market, 2014 - 2025 (USD Million)
  • FIG. 32 Regional market place: Key takeaways
  • FIG. 33 Regional outlook, 2016 & 2025
  • FIG. 34 Strategy framework
  • FIG. 35 Market participation and categorization
Back to Top